William J. Gradishar, MD, on Innovating Pathways for Patient Self-Management in Breast Cancer
NCCN 2020 Virtual Annual Conference
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the “4R Model” (Right Information, Care, Patient, and Time) which has proved to be a promising method for patient self-management. Patient care sequence plans markedly improved several aspects of patient self-management, as well as delivery of multimodality care (Abstract BPI20-017).
The ASCO Post Staff
Apar Kishor Ganti, MD, of the University of Nebraska Medical Center, discusses his study findings, which show that alectinib was associated with longer treatment persistence and comparable adherence to other ALK inhibitors (Abstract HSR20-084).
The ASCO Post Staff
Christopher D'Avella, MD, of Fox Chase Cancer Center, discusses the impact of his institution’s oncologic urgent care center, designed to triage patients and prevent hospital admissions. Patients who presented to the direct referral unit had lower health-care expenses vs those who went to the emergency department (Abstract HSR20-081).
The ASCO Post Staff
Barbara DeVivo, PhD, MBA, of Westmont College, talks about how the culture and structure of tumor boards—and their invisible status hierarchies—may hamper collaboration and influence the way providers treat patients with cancer (Abstract BPI20-020).
The ASCO Post Staff
Pam Baker DeGuzman, PhD, of the University of Virginia School of Nursing, discusses her study findings on the use of the NCCN Distress Thermometer, which identified and addressed distress in patients treated for head and neck cancer who were then referred to speech pathologists, lymphedema specialists, and social workers (Abstract HSR20-082).
The ASCO Post Staff
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses racial differences in self-reported outcomes of patients with HER2-negative, locally advanced or metastatic breast cancer and a germline BRCA1/2 mutation who received talazoparib vs physician’s choice of chemotherapy (Abstract CLO20-039).
